Diplomat Pharmacy, Inc. (NYSE:DPLO) entered into a definitive agreement to acquire Affinity Biotech, Inc. for $20 million in cash on January 9, 2017. Under the terms of the agreement, the consideration comprises of $4 million on contingent consideration. Affinity Biotech reported revenue of $27 million and EBITDA of $3 million in 2016. The deal is expected to close in February, 2017. Bob East of Westwicke Partners acted as public relation advisor for Diplomat Pharmacy. Philip Desai, Michael D. DuBay of Honigman Miller Schwartz and Cohn LLP acted as a legal advisor to Diplomat Pharmacy, Inc.